Search
News Chat
Login
Search
Top
For You
Business
Crypto
Culture
Environment
Politics
Science
Sports
Tech
Video Games
World
Vertex Pharmaceuticals News
VRTX
VERTEX PHARMACEUTICALS INC
470.28
-0.74%
VRTX
VERTEX PHARMACEUTICALS INC
470.28
-0.74%
Top stories
Vertex Reports Positive Results in Phase 1/2 Study of VX-880 for Type 1 Diabetes at ADA2024 in Orlando
Authors
6
12 days
Bio
Science
NHS England to Offer Kaftrio, Symkevi, Orkambi After Deal with Vertex
Authors
8
14 days
Bio
Science
Articles
Latest stories
Vertex Reports Positive Results in Phase 1/2 Study of VX-880 for Type 1 Diabetes at ADA2024 in Orlando
Authors
6
12 days
Bio
Science
NHS England to Offer Kaftrio, Symkevi, Orkambi After Deal with Vertex
Authors
8
14 days
Bio
Science
Vertex Pharmaceuticals Reaches Pricing Deal with NHS for Cystic Fibrosis Drugs
Authors
5
14 days
Economics
Business
29 of 30 Patients Benefit from FDA-Approved Gene Editing Therapy for Sickle Cell
Authors
6
2 months
Bio
Science
Vertex Pharmaceuticals Acquires Alpine Immune Sciences for $4.9 Billion in Cash, IgA Nephropathy, 171% Premium
Authors
18
3 months
Economics
Bio
Crime
Vertex's Largest-Ever Buyout: Acquires Alpine for $65/Share, a 72.3% Premium
Authors
36
3 months
Economics
Business
Goldman Removes Apple $AAPL from Conviction List, Raises PT to $232, Adds Amgen, Monday, Vulcan Materials, Removes Merck, Vertex
Authors
9
4 months
Economics
Business
Breakthrough Sickle Cell Therapies' 7-Figure Cost Poses Access Challenges
Authors
4
4 months
Economics
Business
Latigo Biotherapeutics Launches $135M for Non-Opioid Pain Medicine, Competes with Vertex Pharmaceuticals
Authors
9
5 months
Bio
Science
Vertex Shares Up 1.2% on Earnings Beat, New CF Drug; Eli Lilly Beats with $9.35B Revenue
Authors
9
5 months
Economics
Business
Vertex Pharmaceuticals' VX-548 Succeeds in Phase 3 Trials for Acute Pain; Misses Secondary Endpoint vs. Hydrocodone, Plans NDA Submission and FDA Approval
Authors
29
5 months
Bio
Science
CRISPR Gene-Editing Therapy for Sickle Cell Disease Gains US and European Regulatory Approval, Sparks Criticism After SNL Skit, Includes Alzheimer’s Drug and RSV Vaccines
Authors
13
7 months
Science
Vertex Pharmaceuticals' Stock Surges 7.5% on Positive VX-548 Trial Results
Authors
9
7 months
Economics
Business
Vertex's Non-Opioid Painkiller Shows Promise in Diabetic Nerve Pain Trial, Stock Gains, Pivotal Trials Ahead
Authors
7
7 months
Economics
Business
FDA Approves Bluebird Bio's Lyfengia with Black Box Warning; Vertex's Casgevy Priced at $2.2 Million, Shares Plunge 42%
Authors
4
7 months
Economics
Business
Vertex Pharmaceuticals and U.K. Government Agency Clash over Cystic Fibrosis Medicines, BioNTech Cuts Revenue Forecast, Vertex Pharma Misses Sales Estimates
Authors
4
8 months
Economics
Business
Amgen's Patent Maneuvers Considered in Medicare Drug Price Negotiations; Novo Nordisk Warns EU Rules Will Push Expansion in US; EU Could Lose €2 Billion Investment in Medicines R&D; Europe's Share in Global R&D May Decline to 21% by 2040; Medicare Proposes Hospital Price Transparency; Vertex Pharmaceuticals in Dispute Over Cystic Fibrosis Medicines
Authors
9
8 months
Economics
Business
FDA Advisory Committee to Review Vertex Pharmaceuticals' exa-cel CRISPR Gene Editing Therapy for Sickle Cell Disease
Authors
28
8 months
Economics
Business
Previous
Next